Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
Abstract Introduction Psoriasis may increase risk for comorbid diabetes and obesity. Tildrakizumab, an anti-interleukin-23 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis, was evaluated in the pivotal phase 3 trials reSURFACE 1 and reSURFACE 2. This...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare
2026-03-01
|
| Seri Bilgileri: | Dermatology and Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s13555-026-01708-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|